Immutep Completes Phase II recruitment
- Immutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer
- The last patient has now been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study
- Patients are now participating across three parts of the study, in 20 clinical sites in Australia, Europe and the US
- The company says its clinical team and partners have worked hard to continue the pace of patient enrolment and finished recruitment earlier than originally anticipated
- The company is up 0.92 per cent, trading at 55 cents at 11:20 am AEDT
